"A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study." by Uday B. Dandamudi

Selected Works of Walter J. Urba, MD, PhD

Article

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Journal of Immunotherapy (2013)

Uday B. Dandamudi, Dartmouth College
Musie Ghebremichael, Harvard University
Jeffrey A. Sosman, Vanderbilt University
Joseph I. Clark, Loyola University Chicago
David F. McDermott, Harvard University
Michael B. Atkins, Georgetown University
Janice P. Dutcher, Mount Sinai St. Luke's and Mount Sinai Roosevelt
Walter J. Urba, Providence Portland Medical Center
Meredith M. Regan, Harvard University
Igor Puzanov, Vanderbilt University
Todd S. Crocenzi, Providence Health & Services
Brendan D. Curti, Providence Portland Medical Center
Ulka N. Vaishampayan, Wayne State University
Nancy A. Crosby, Dartmouth College
Kim A. Margolin, University of Washington
Marc S. Ernstoff, Dartmouth College

Link

Disciplines

Publication Date

January 1, 2013

DOI

10.1097/CJI.0000000000000003

Citation Information

Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman, Joseph I. Clark, et al.. "A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study." Journal of Immunotherapy Vol. 36 Iss. 9 (2013) p. 490 - 495
Available at: http://works.bepress.com/walter-urba/146/